BioSpace News Archive

Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Brazil’s health regulatory agency, ANVISA, the equivalent of the US Food and Drug Administration, has given an approval to market Sofwave’s™ SUPERB device in Brazil.

SELLAS Life Sciences Group, Inc. today provides webcast information for its virtual investor event on November 14, 2022, at 8:30 a.m. ET. at which the Company will provide an update on its Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia.

Evoke Pharma, Inc. today announced that the Company is scheduled to release its third quarter on Wednesday, November 9, 2022, after the market closes.

Precision Optics Corporation, Inc. (OTCQB: PEYE) (the “Company”) announced today that the planned 1-for-3 reverse split of its common stock became effective after the close of business on Tuesday, November 1, 2022 (the “Effective Time”).

Thryv Therapeutics Inc. today announced two presentations on the results of SGK1 Inhibition in Patient- and Genotype Specific Re-Engineered Heart Cells with Congenital Long QT Syndrome and a model of Drug-Induced QT Prolongation at the American Heart Association Scientific Sessions 2022 taking place November 5-7, 2022, in Chicago, IL.

Fresenius Medical Care North America, the nation’s leading dialysis products company, announced the U.S. Food and Drug Administration 510 clearance upgrading the company’s Liberty® Select Cycler to enable remote therapy management with the Kinexus® Therapy Management Platform.

Ardelyx, Inc. announced that on October 26, 2022, the compensation committee of the company’s board of directors granted three new non-executive employees options to purchase an aggregate of 127,907 shares of the company’s common stock, and an aggregate of 31,875 Restricted Stock Units.

Protagonist Therapeutics announced the appointment of Arturo Molina, M.D., M.S., F.A.C.P. to the role of Chief Medical Officer, effective November 7, 2022.

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2022 and provided a corporate update.

ChromaDex Corp. announced financial results for the third quarter of 2022.